FDA Approves Hibsago, First Antisense Drug for Hepatitis B

HibsagoWhat to know

30-second read

For Infectious Disease · Gastroenterology · Internal Medicine

Who

Adults with chronic hepatitis B, without cirrhosis, stable on a nucleos(t)ide analogue (NA) ≥6 months, HBV DNA suppressed, HBsAg ≤3,000 IU/mL.

What’s new

Hibsago (bepirovirsen) — the first antisense oligonucleotide for chronic HBV — added to existing NA therapy for a finite, 24-week course.

Evidence

Pooled B-Well 1/2 (1,834 adults): 19% functional cure 24 weeks post-treatment vs 0% placebo; 26% if baseline HBsAg ≤1,000 IU/mL.

Big advantage

A real, if narrow, route off indefinite antiviral therapy: 24% of recipients also met criteria to stop their background NA at week 48, versus none on placebo.

Key consideration

Boxed warning: hepatic flares and thrombocytopenia (contraindicated if platelets <100 × 10&sup9;/L); weekly platelet checks required.

Availability

Approved 20 October 2026, six days ahead of its PDUFA date. No U.S. price or coverage policy announced; a companion diagnostic is required to confirm eligibility.

Practice impactConsider for selected patients

A genuine new option for the minority of stable, non-cirrhotic patients who want a defined shot at stopping therapy — not a reason to reopen management for patients doing well on NA monotherapy alone.

Read the full physician analysis

Full analysis · 9 min readFDA approval, 20 Oct 2026 · GSK · B-Well 1/2, NEJM (2026)

The FDA approved GSK’s Hibsago (bepirovirsen) on 20 October 2026 for chronic hepatitis B in a defined adult population — six days ahead of its PDUFA target date, and the first antisense oligonucleotide ever cleared for the indication. It is not a replacement for the nucleos(t)ide analogues (NAs) that already suppress HBV effectively; it is a finite, 24-week add-on aimed at an outcome NA therapy almost never delivers on its own — a defined route to stopping treatment altogether.

What an antisense drug does that an antiviral doesn’t

NAs — entecavir, tenofovir and their relatives — block HBV from replicating, which is why patients on them typically have undetectable viral DNA within months. What NAs rarely touch is hepatitis B surface antigen (HBsAg), the viral protein whose persistence is why hepatologists keep patients on therapy indefinitely. Bepirovirsen works differently: it is a short synthetic strand of antisense chemistry, licensed from Ionis Pharmaceuticals, designed to bind HBV messenger RNA and reduce production of HBsAg and other viral proteins directly. Given alongside an NA rather than instead of one, it is the first approved mechanism aimed squarely at the protein that keeps patients tethered to lifelong treatment.

Two trials, two different finish lines

B-Well 1 and B-Well 2 were identical Phase 3 trials that together randomized 1,834 non-cirrhotic adults, stable on NA therapy for at least six months, 2:1 to weekly subcutaneous bepirovirsen (300 mg, given as two injections) or placebo for 24 weeks, with the NA continued throughout. The trials tracked two distinct outcomes that matter separately to a treating physician. The first, assessed at week 48, was whether a patient had suppressed HBV DNA and HBsAg low enough to justify stopping the background NA; 24% of bepirovirsen recipients met that bar against none on placebo. The second and more stringent outcome — functional cure, defined as sustained loss of HBsAg and HBV DNA below the limit of quantification — was assessed 24 weeks after all treatment stopped, around week 72. There, bepirovirsen reached 20% in B-Well 1 (127 of 650) and 19% in B-Well 2 (106 of 570), against zero placebo responders in either trial, published together in the New England Journal of Medicine. Patients who started with lower baseline HBsAg (≤1,000 IU/mL) did better still, at 26%.

B-Well 1 and B-Well 2, pooled

19% vs 0%Functional cure 24 weeks after stopping all treatment, bepirovirsen vs placebo (233 of 1,220 vs 0 of 614)

26%Functional cure rate in the subgroup with baseline HBsAg ≤ 1,000 IU/mL

24% vs 0%Met criteria to discontinue the background NA at week 48, bepirovirsen vs placebo

1,834Adults randomized across both trials, 2:1 to bepirovirsen or placebo, NA continued throughout

B-Well 1 and B-Well 2 (NEJM, 2026); FDA approval announcement, 20 October 2026. A functional cure is not viral eradication — HBV can persist in latent form — but it is the outcome hepatologists treat as the practical treatment goal.

A diagnostic test decides who is actually eligible

The label is built around a lab value, and FDA authorized a specific companion diagnostic to measure it: Roche’s Elecsys HBsAg II quant II RxDx assay confirms a patient’s HBsAg is at or below the 3,000 IU/mL cutoff before Hibsago can be prescribed, and is used again during treatment to track response. That is a workflow change before it is a prescribing decision — practices will need to confirm the assay is available through their lab or reference lab, not assume a routine HBsAg result from a different platform satisfies the label.

The boxed warning that will shape the first six months

Hibsago carries a boxed warning for two distinct risks. On-treatment hepatic flares — ALT rises of 20 to 40 times the upper limit of normal, sometimes with hyperbilirubinemia — occurred in trial patients, mostly within the first 12 weeks, and generally resolved when treatment was interrupted or stopped; the label directs against starting Hibsago in anyone with acute hepatic impairment or cirrhosis. Separately, bepirovirsen can cause sudden, unpredictable drops in platelet count: the drug is contraindicated at a baseline platelet count under 100 × 10&sup9;/L, and the label calls for platelet monitoring at least weekly through the 24-week course. FDA’s labeling also warns of worsening renal function and serious inflammatory reactions, including vasculitis. None of this is exotic for a subcutaneous antisense or siRNA therapy, but it is a materially heavier monitoring load than refilling an NA prescription, and it is the main reason this will not become a reflexive add-on for every eligible patient.

A finite course against an open-ended one

Today's standard versus adding Hibsago

	NA monotherapy (today's standard)	NA + Hibsago (bepirovirsen)
Treatment horizon	Open-ended; most patients remain on therapy indefinitely	24-week add-on course, then reassessment
Functional cure rate	Rare on NA monotherapy alone	19% at 24 weeks post-treatment (26% in lower-HBsAg patients)
Who qualifies	Broad — most patients with chronic HBV needing suppression	Narrow — non-cirrhotic, stable ≥6 months, HBsAg ≤3,000 IU/mL
Monitoring	Periodic HBV DNA and liver function checks	Weekly platelets during treatment, ALT monitoring, companion HBsAg assay
Administration	Oral, once daily	Subcutaneous injection, weekly for 24 weeks (self-administered after the first dose)

Hibsago is given with the existing NA, not instead of it. Figures from the B-Well 1/2 pooled results and FDA's approval announcement, 20 October 2026.

What a practice needs before prescribing

• Patient identification. Screen the existing non-cirrhotic HBV panel for stable NA use ≥ 6 months with suppressed HBV DNA; confirm eligibility with the Roche companion HBsAg assay rather than a routine result from a different platform.
• Counseling before the first dose. Weekly self-injection for 24 weeks, continuing the existing NA; the realistic chance of a functional cure is roughly one in five, not a guarantee, and is higher for patients who start with lower HBsAg.
• Monitoring infrastructure. A practice offering Hibsago needs a protocol for weekly platelet checks and ALT monitoring through the course, plus a week-48 and week-72 assessment — not a one-time prescribing decision.
• Who to flag for referral. Patients with cirrhosis or acute hepatic impairment should not start Hibsago; primary care and internal medicine identifying hepatitis B patients should route eligible, stable candidates to a hepatologist or infectious disease specialist experienced with the boxed warning.
• Coverage conversations now, not later. With no published price or payer policy, expect prior authorization and specialty-pharmacy routing once Hibsago reaches the market — worth setting expectations with patients before, not after, a positive eligibility screen.

The honest caveat is durability: GSK has followed a small cohort of patients who reached functional cure in earlier-stage studies for up to three years and reports most remain in remission, but that is a small, uncontrolled follow-on observation, not a confirmatory trial, and hepatologists are right to want longer data before calling this cure permanent. What the B-Well trials do establish cleanly is that, for a defined and fairly narrow slice of stable chronic hepatitis B patients, there is now an FDA-approved, evidence-backed path to attempt stopping treatment — something lifelong NA therapy was never designed to offer.

How Hibsago got here, and where it stands abroad

1. Aug 2024

   SENKU designation in Japan

   Japan's MHLW grants expedited-review status, Japan's first regulatory engagement with bepirovirsen.

2. Feb 2026

   Japan NDA accepted

   MHLW accepts GSK's new drug application for review, the first global regulatory filing.

3. Aug 2026

   Japan approves Hibsago

   The first global approval, for functional-cure-intent use in adults meeting the same viral-marker criteria.

4. 20 Oct 2026

   FDA approves Hibsago

   Six days ahead of the PDUFA date; the first antisense therapy cleared for chronic hepatitis B in the U.S.

5. Ahead

   Australia and the EU

   Australia's TGA has accepted an application; a European regulatory review is reported underway, with no confirmed decision date.

Frequently asked questions

Which patients actually qualify for Hibsago?

Adults with chronic hepatitis B, without cirrhosis, who have been on a stable nucleos(t)ide analogue (NA) for at least six months, with HBV DNA suppressed and HBsAg at or below 3,000 IU/mL as measured by the FDA-authorized companion assay (Roche's Elecsys HBsAg II quant II RxDx test). It is given alongside the existing NA, not in place of it, and patients with acute hepatic impairment or cirrhosis should not start it.

How often do patients actually reach a functional cure?

In the pooled B-Well 1 and B-Well 2 Phase 3 trials (1,834 adults), 19% of bepirovirsen recipients had a functional cure — sustained loss of HBsAg and undetectable HBV DNA — 24 weeks after stopping all treatment, versus 0% on placebo. The rate rose to 26% in patients who started with lower baseline HBsAg (≤1,000 IU/mL). Separately, 24% of recipients met the bar to stop their background NA at week 48, versus none on placebo.

What does the boxed warning actually require in practice?

Check platelets before starting — Hibsago is contraindicated below 100 × 10⁹/L — and at least weekly during the 24-week course, with liver enzymes also monitored for on-treatment hepatic flares (ALT rises of 20–40× the upper limit of normal have occurred, mostly in the first 12 weeks). The label also warns of worsening renal function and serious inflammatory reactions, including vasculitis.

Is Hibsago covered by insurance yet?

Unknown. GSK has not announced a list price, and coverage policy from Medicare or commercial payers has not been published. As a specialty, self-injected biologic-class product, expect it to route through the pharmacy benefit with prior authorization once a price is set — that is inference from how comparable specialty injectables are typically handled, not a confirmed Hibsago-specific policy.